Plain-English translation of NCT06425133 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding low-dose metronomic chemotherapy and aspirin to a medication called works better than alone for people with advanced colorectal cancer that has progressed despite previous treatments. is a targeted drug that slows cancer growth by blocking specific proteins. The study will compare how long patients live without their cancer getting worse on each treatment approach.
Standard treatments for advanced bowel cancer eventually stop working for many patients, leaving them with limited options. This trial is exploring whether this medication might work more effectively when combined with other low-dose treatments, potentially offering hope to patients whose cancer has become resistant to earlier therapies.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either alone or combined with low-dose metronomic chemotherapy and aspirin. In your first month, the dose of the medication will be gradually increased to find your best tolerated dose. After that, you'll take the medication for 3 weeks out of every 4-week cycle until your cancer progresses or side effects become too severe. You'll have regular blood tests and imaging scans to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France